Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase I/II clinical trials and TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); and TLX66, which is in Phase I/IIa clinical trials for the treatment of bone marrow conditioning and rare diseases. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; TLX591-Sx, a positron emission tomography (PET) tracer that delivers PET and fluorescent (optical) imaging; and TLX599-CDx, an investigational prostate cancer imaging agent that uses single photon emission computed tomography. It has a strategic license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for developing a portfolio of MTR products; scientific and clinical research collaboration with Mauna Kea Technologies; and strategic collaboration agreement with Lightpoint Medical, Ltd. The company was founded in 2015 and is headquartered in North Melbourne, Australia.

Telix Pharmaceuticals Limited

Telix Medical

Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic ('theranostic') radiopharmaceuticals. Telix is headquartered in Melbourne, Australia with commercial operations in the United States, Europe (Belgium and Switzerland) and Japan. Telix is developing a portfolio of radiopharmaceutical products that aims to address significant unmet medical need in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX).

To all our collaborators, colleagues and friends celebrating the #LunarNewYear, Telix wishes a safe and prosperous Year of the Dragon. 

Telix is proud to be working with our partners to deliver the promise of targeted radiation to patients across Asia, including in Greater China where 25% of global cancer cases occur. 

In China, the Phase III registration study of TLX591-CDx (Illuccix®, Kit for the preparation of 68Ga-PSMA-11) has now reached its 50% recruitment milestone, bringing advanced PSMA-PET imaging one step closer for Chinese men with prostate cancer.   

We look forward to working together in 2024 to help patients with cancer and rare diseases across the region live longer, better quality lives. 

Illuccix has been approved by the U.S. FDA, by the Australian TGA, and by Health Canada. In all other countries it is for investigational use only.

Telix today announces that it has entered into an agreement to acquire QSAM Biosciences, Inc. and its bone cancer targeting platform, Samarium-153-DOTMP (153Sm-DOTMP). 

With two major potential applications – pain management of bone metastases and osteosarcoma therapy – 153Sm-DOTMP is a highly synergistic addition to Telix’s existing therapeutic focus areas in prostate cancer, glioma (brain cancer) and sarcoma.

The acquisition, subject to customary closing conditions including regulatory approvals, will further enhance the potential of Telix’s near-term therapeutic pipeline with an asset that has strong potential for a rapid pathway to commercialisation. 

Refer to our website and ASX disclosures for further details: https://lnkd.in/gHPsSwrG

153Sm-DOTMP has not received a marketing authorisation in any jurisdiction.

Telix will release its full year results and Annual Report for the period ended 31 December 2023 on Thursday 22 February 2024.

An investor webcast will be held at 9:00am AEDT on Friday 23 February 2024 (5:00pm EST, Thursday 22 February) including an update on Telix’s operations.

To register for the webcast visit: https://lnkd.in/gtZpS64T

Today, on World Cancer Day, we pause to recognise all those affected by cancer and renew our commitment to working towards a world where preventable cancer deaths are saved and access to care is equitable.

Telix is committed to reducing healthcare disparities by developing innovative radiopharmaceuticals that help to improve the lives of patients wherever they live. 

Click below to learn more about the Cancer Care Gap and take a step to Close the Gap by visiting worldcancerday.org

#WorldCancerDay #CloseTheCareGap

Telix is live at American Society of Clinical Oncology (ASCO) GU 2024 in San Francisco!

Come and meet the team at booths #60 & #67 to learn about our differentiated antibody-based platforms and late-stage PSMA- and CAIX- targeting theranostic programs being developed as part of Telix's industry-leading pipeline in urology.

More on our presence at ASCO GU including details of abstract presentations here: telixpharma.com/ascogu24

#GU24 #ASCOGU

COM:TELIXPHARMA